Bangladesh Pharmaceutical and Bio Market: Entry Opportunities for Korean Companies
Bangladesh's pharmaceutical industry has a strong manufacturing base that covers 97% of the domestic market through domestic production, and is a South Asian pharmaceutical hub that exports to more than 150 countries. With a market size of approximately $4.5 billion as of 2024 and growth exceeding 15% annually, the sector represents a significant opportunity for Korean bio and pharmaceutical companies across diverse entry formats — including active pharmaceutical ingredient (API) exports, technology licensing, medical device sales, and biosimilar co-development.
KOTRA's Dhaka trade office has actively pursued matching between Korean bio and pharmaceutical companies and Bangladesh pharmaceutical companies, accumulating 5+ successful buyer matching cases in recent years. This article analyzes concrete matching cases alongside Bangladesh entry strategies in the bio and pharmaceutical sector from a practical standpoint.
5 Successful Buyer Matching Cases
The following analyzes Bangladesh market entry matching cases for Korean bio and pharmaceutical companies facilitated through KOTRA's Dhaka trade office. Each case documents what products were involved, how they were connected, which buyers were matched, and what the success factors were.
| Case | Korean Company Sector | Matching Type | Bangladesh Buyer | Contract Scale |
|---|---|---|---|---|
| Case 1 | Active Pharmaceutical Ingredients (API) | Export contract | Square Pharma affiliate | $500K+/year |
| Case 2 | In Vitro Diagnostic (IVD) Kits | Exclusive dealer contract | Popular Medical affiliate | $300K+/year |
| Case 3 | Biosimilars | Technology licensing MOU | Beximco Pharma affiliate | Under negotiation |
| Case 4 | Dental Materials | Export contract | Dental distribution agent | $150K+/year |
| Case 5 | Health Functional Foods | Distribution partnership | Beauty and health distributor | $200K+/year |
Case 1: Active Pharmaceutical Ingredient (API) Export
Korean Company A, a mid-sized pharmaceutical manufacturer specializing in antibiotic-class active pharmaceutical ingredients, signed an annual export contract of $500,000+ in APIs with an affiliate of Square Pharmaceuticals, Bangladesh's largest pharmaceutical company. Bangladesh pharmaceutical companies need stable supply sources for high-quality APIs to produce generic drugs, and the quality consistency and GMP compliance of Korean APIs — compared to Chinese and Indian APIs — proved to be the decisive competitive advantage.
Case 2: In Vitro Diagnostic (IVD) Kit Exclusive Dealer Contract
Korean Company B, a medical device manufacturer producing IVD products including blood glucose meters and rapid diagnostic test (RDT) kits, signed an exclusive dealer contract with a Bangladesh medical device distributor. With Bangladesh's diabetic population surging to over 8.3 million, demand for blood glucose meters is growing explosively, and the accuracy and competitive price point of Korean products secured a competitive advantage over Indian and Chinese alternatives.
Case 3: Biosimilar Technology Licensing
Korean Company C, a bio-venture developing oncology biosimilars, signed a technology licensing MOU with a major Bangladesh pharmaceutical company. Bangladesh can produce biosimilars at low cost by leveraging its TRIPs exemption until 2032, giving it high appeal as a technology licensing partner for Korean bio companies.
Sector-by-Sector Entry Strategies
Bangladesh entry strategies in the bio and pharmaceutical sector differ by product type. The following presents the optimal entry pathway for each sector: APIs, finished pharmaceuticals, medical devices, and biosimilars.
Despite a 97% self-sufficiency rate, Bangladesh's pharmaceutical and bio market remains highly dependent on imports for active pharmaceutical ingredients, advanced medical devices, and biosimilar technology. Korean companies can secure a meaningful position in this market by leveraging GMP quality competitiveness, biosimilar technology, and digital healthcare solutions. While actively using KOTRA's Dhaka trade office matching service, a long-term entry plan that accounts for the extended timeframe of DGDA registration procedures is essential.